The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats

Journal of Drug Targeting

Volumn 19, Issue 5, 2011, Pages 382-390

  Zhao, Bo Jun ^a   Ke, Xi Yu ^a   Huang, Yue ^a   Chen, Xiao Mei ^a   Zhao, Xin ^a   Zhao, Bing Xiang ^a   Lu, Wan Liang ^a   Lou, Jin Ning ^b   Zhang, Xuan ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

Aminopeptidase N (APN); antitumor efficacy; Asn Gly Arg (NGR); brain glioma bearing rats; DSPE PEG micelles; paclitaxel (PTX)

Indexed keywords

1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; ASPARAGYLGLYCYLARGININE PEPTIDE; GLYCEROPHOSPHOETHANOLAMINE; MACROGOL 2000; NANOCARRIER; PACLITAXEL; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG PENETRATION; ENDOTHELIUM CELL; GLIOMA; GLIOMA CELL; HYDRATION; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MICELLE; MICROENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; TUMOR CELL DESTRUCTION; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; ENDOTHELIAL CELLS; FLOW CYTOMETRY; GLIOMA; GLUTAMYL AMINOPEPTIDASE; MALE; MICE; MICELLES; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; PACLITAXEL; PARTICLE SIZE; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79955623052     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2010.504267     Document Type: Article

References (40)

1. Folkman J. (1996). Fighting cancer by attacking its blood supply. Sci Am, 275, 150-154.
2. Sato TN. (1998). A new approach to fighting cancer? Proc Natl Acad Sci USA, 95, 5843-5844. (Pubitemid 28248927)
3. Byrne JD, Betancourt T, Brannon-Peppas L. (2008). Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev, 60, 1615-1626.
4. Arap W, Pasqualini R, Ruoslahti E. (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279, 377-380. (Pubitemid 28063372)
5. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E. (2000). Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res, 60, 722-727. (Pubitemid 30094573)
6. Shim JS, Kim JH, Cho HY, Yum YN, Kim SH, Park HJ, Shim BS, Choi SH, Kwon HJ. (2003). Irreversible inhibition of CD13/ aminopeptidase N by the antiangiogenic agent curcumin. Chem Biol, 10, 695-704. (Pubitemid 37089844)
7. Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, Corti A. (2002). Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res, 62, 867-874. (Pubitemid 34126966)
8. van Hensbergen Y, Broxterman HJ, Elderkamp YW, Lankelma J, Beers JC, Heijn M, Boven E, Hoekman K, Pinedo HM. (2002). A doxorubicin-CNGRC-peptide conjugate with prodrug properties. Biochem Pharmacol, 63, 897-908. (Pubitemid 34243003)
9. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, Bredesen DE, Pasqualini R. (1999). Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med, 5, 1032-1038. (Pubitemid 29439574)
10. Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M. (2003). Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res, 63, 7400-7409. (Pubitemid 37413482)
11. Garde SV, Forté AJ, Ge M, Lepekhin EA, Panchal CJ, Rabbani SA, Wu JJ. (2007). Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anticancer Drugs, 18, 1189-1200. (Pubitemid 47480744)
12. Holland EC. (2001). Progenitor cells and glioma formation. Curr Opin Neurol, 14, 683-688. (Pubitemid 34060103)
13. Cimini A, Cristiano L, Colafarina S, Benedetti E, Di Loreto S, Festuccia C, Amicarelli F, Canuto RA, Cerù MP. (2005). PPARgamma-dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF). Int J Cancer, 117, 923-933. (Pubitemid 41688566)
14. Koo YE, Reddy GR, Bhojani M, Schneider R, Philbert MA, Rehemtulla A, Ross BD, Kopelman R. (2006). Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev, 58, 1556-1577. (Pubitemid 44820505)
15. Pardridge WM. (2001). BBB-Genomics: creating new openings for brain-drug targeting. Drug Discov Today, 6, 381-383. (Pubitemid 32328285)
16. Puduvalli VK, Sawaya R. (2000). Antiangiogenesis - therapeutic strategies and clinical implications for brain tumors. J Neurooncol, 50, 189-200. (Pubitemid 32166301)
17. Kunz J, Krause D, Kremer M, Dermietzel R. (1994). The 140-kDa protein of blood-brain barrier-associated pericytes is identical to aminopeptidase N. J Neurochem, 62, 2375-2386. (Pubitemid 24179522)
18. Rowinsky EK, Cazenave LA, Donehower RC. (1990). Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst, 82, 1247-1259. (Pubitemid 20239995)
19. Gelderblom H, Verweij J, Nooter K, Sparreboom A. (2001). Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer, 37, 1590-1598. (Pubitemid 32778603)
20. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G. (1996). The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res, 2, 1843-1849. (Pubitemid 26384151)
21. Ng SS, Figg WD, Sparreboom A. (2004). Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res, 64, 821-824. (Pubitemid 38176878)
22. Ong BY, Ranganath SH, Lee LY, Lu F, Lee HS, Sahinidis NV, Wang C.H. (2009). Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. Biomaterials, 30, 3189-3196.
23. Ranganath SH, Wang CH. (2008). Biodegradable microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant glioma. Biomaterials, 29, 2996-3003.
24. Kastantin M, Ananthanarayanan B, Karmali P, Ruoslahti E, Tirrell M. (2009). Effect of the lipid chain melting transition on the stability of DSPE-PEG(2000) micelles. Langmuir, 25, 7279-7286.
25. Chen XM, Wang X, Huang Y, Zhang X, Zhang Q. (2009). A comparison study of the targeting properties of NGR-liposomes and RGD-liposomes towards human umbilical vein endothelial cells. J Chin Pharm Sci, 18, 162-169.
26. Zhang XC, Jackson JK, Burt HM. (1996). Development of amphiphilic diblock copolymers as micellar carriers of taxol. Inter J Pharm 132, 195-206. (Pubitemid 26158719)
27. Vichai V, Kirtikara K. (2006). Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc, 1, 1112-1116.
28. von Eckardstein KL, Patt S, Kratzel C, Kiwit JC, Reszka R. (2005). Local chemotherapy of F98 rat glioblastoma with paclitaxel and carboplatin embedded in liquid crystalline cubic phases. J Neurooncol, 72, 209-215. (Pubitemid 40867402)
29. Baskaya MK, Dogan A, Rao AM, Dempsey RJ. (2000). Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury. J Neurosurg, 92, 448-452. (Pubitemid 30112386)
30. Petrangolini G, Supino R, Pratesi G, Dal Bo L, Tortoreto M, Croce AC, Misiano P, Belfiore P, Farina C, Zunino F. (2006). Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins. J Pharmacol Exp Ther, 318, 939-946. (Pubitemid 44268298)
31. Liu XR, Wu KC, Huang Y, Sun JB, Ke XY, Wang JC, Lu WL, Zhang X, Zhang Q. (2008). In vitro and in vivo studies on plasma-to-blood ratio of paclitaxel in human, rabbit and rat blood fractions. Biol Pharm Bull, 31, 1215-1220. (Pubitemid 351871182)
32. Pardridge WM. (2007). Drug targeting to the brain. Pharm Res, 24, 1733-1744. (Pubitemid 47206623)
33. Kirsch M, Schackert G, Black PM. (2000). Anti-angiogenic treatment strategies for malignant brain tumors. J Neurooncol, 50, 149-163. (Pubitemid 32166297)
34. Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K, Wolff K, Petzelbauer P. (2003). Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J Invest Dermatol, 120, 476-482. (Pubitemid 36298435)
35. Schmitt-Sody M, Strieth S, Krasnici S, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K, Dellian M. (2003). Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res, 9, 2335-2341. (Pubitemid 36687660)
36. Strieth S, Eichhorn ME, Sauer B, Schulze B, Teifel M, Michaelis U, Dellian M. (2004). Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer, 110, 117-124. (Pubitemid 38507211)
37. Strieth S, Nussbaum CF, Eichhorn ME, Fuhrmann M, Teifel M, Michaelis U, Berghaus A, Dellian M. (2008). Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int J Cancer, 122, 452-460. (Pubitemid 350234735)
38. Strieth S, Eichhorn ME, Werner A, Sauer B, Teifel M, Michaelis U, Berghaus A, Dellian M. (2008). Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin. Clin Cancer Res, 14, 4603-4611.
39. Bode C, Trojan L, Weiss C, Kraenzlin B, Michaelis U, Teifel M, Alken P, Michel MS. (2009). Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer. Oncol Rep, 22, 321-326.
40. Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K. (2001). Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. J Control Release, 77, 27-38. (Pubitemid 33022613)